PROC and Hypofibrinogenemia: Six studies submitted for meta-analysis demonstrated that coagulation abnormalities, including hypofibrinogenemia and elevated activated protein C, result in adverse outcomes with a pooled HR of 6.3 (95% CI: 3.04-13.05, p < 0.05).